The Evidence Based Reimbursement Summit

Part I: Generating Evidence for Reimbursement Decisions: Therapeutics

It is important to formulate goals for generating, collecting, and analyzing reimbursement evidence early in product development in order to ensure commercial success of a drug or a biologics. We are witnessing the emergence of a new integrated strategy while the biopharmaceutical industry is partnering up with payers to develop evidence of a product’s validity and utility as well as comparative clinical and cost effectiveness. The inaugural Generating Evidence for Reimbursement Decisions: Therapeutics conference is designed to bring together all major stakeholders in the field of evidence-based reimbursement, clinical development experts, reimbursement and government affairs specialists, health care economists and payers. The conference will be directly followed by Generating Evidence for Reimbursement Decisions: Diagnostics conference.

Part II: Generating Evidence for Reimbursement Decisions: Diagnostics 

Achieving commercial success for an IVD product or device is becoming progressively more difficult in the current healthcare environment. The combination of tightening health care budget and launch of a large number of expensive molecular tests creates complications for payers to respond in traditional ways. Comprehensive clinical data and pharma-type clinical trials have increasingly become the condition of getting a test reimbursed. The inaugural Generating Evidence for Reimbursement Decisions: Diagnostics conference is designed to bring together major players the field of evidence-based reimbursement in diagnostics. The conference will be preceded by Generating Evidence for Reimbursement Decisions: Therapeutics conference.